Funding Rounds
HepaRegeniX Series A round, January 2017
HepaRegeniXSmall molecule MKK4 inhibitors to treat acute and chronic liver diseases
Summary
Stage: Series A
Raised Amount: $9.50M
Raised Date: 2017-01-06
Stage: Series A
Raised Amount: $9.50M
Raised Date: 2017-01-06